Posterior Reversible Encephalopathy Syndrome and Systemic Lupus Erythematosus: An Underestimated Association Case report and Review of Pathophysiological Mechanisms
Article Sidebar
Main Article Content
Abstract
Posterior Reversible Encephalopathy Syndrome (PRES) is a rare clinico-radiological entity, and its global incidence remains unknown. It can be observed in various clinical circumstances, notably during Systemic Lupus Erythematosus (SLE). Its diagnosis is radiological, characterized by the appearance of vasogenic edema within the white matter, predominantly in the posterior parieto-occipital regions. The occurrence of PRES in the context of SLE is rare. Brain MRI with diffusion sequences is the examination of choice for diagnosis and follow-up. Controlling hypertension is the cornerstone of treatment and helps minimize sequelae. The objective of our study is to report a clinical case of a patient followed for lupus nephropathy who developed PRES and to describe pathophysiological mechanisms.
We report a case of a 46-year-old female patient with a history of SLE, admitted with impaired consciousness, convulsive seizures, and a hypertensive peak of 170/110 mmHg. Brain imaging confirmed the diagnosis of PRES, reinforcing the clinical suspicion. Treatment mainly consisted of managing arterial hypertension and preventing recurrent seizures. The patient fully recovered without any persistent neurological deficits. PRES is a rare condition, and appropriate management of its clinical manifestations is crucial to prevent both clinical and radiological sequelae.
Article Details
Copyright (c) 2025 Zerouali S, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Clinical Nephrology is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Clinical Nephrology is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
1. Hinchey J, Chaves C, Appigani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500. Available from: https://doi.org/10.1056/nejm199602223340803
2. Wagih A, Mohsen L, Rayan MM, Hasan MM, Al-Sherif AH. Posterior reversible encephalopathy syndrome (PRES): restricted diffusion does not necessarily mean irreversibility. Pol J Radiol. 2015;80:210–6. Available from: https://doi.org/10.12659/pjr.893460
3. Soo Y, Singhal AB, Leung T, Yu S, Mak H, Hao Q, et al. Reversible cerebral vasoconstriction syndrome with posterior leucoencephalopathy after oral contraceptive pills. Cephalalgia. 2010;30(1):42–5. Available from: https://doi.org/10.1111/j.1468-2982.2009.01868.x
4. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-25. Available from: https://doi.org/10.1016/s1474-4422(15)00111-8
5. Guyton AC, Hall JE. Cerebral blood flow, cerebrospinal fluid, and brain metabolism. In: Textbook of Medical Physiology. 12th ed. Philadelphia: Elsevier Saunders; 2011;743–750.
6. Ugurel MS, Hayakawa M. Implications of post-gadolinium MRI results in 13 cases with posterior reversible encephalopathy syndrome. Eur J Radiol. 2005;53:441–449. Available from: https://doi.org/10.1016/j.ejrad.2004.05.015
7. Rabinstein AA, Mandrekar J, Merrell R, Kozak OS, Durosaro O, Fugate JE. Blood pressure fluctuations in posterior reversible encephalopathy syndrome. J Stroke Cerebrovasc Dis. 2012;21:254–58. Available from: https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.03.011
8. Roth C, Ferbert A. Posterior reversible encephalopathy syndrome: long-term follow-up. J Neurol Neurosurg Psychiatry. 2010;81(7):773-777. Available from: https://doi.org/10.1136/jnnp.2009.189647
9. Wu F, Liu L, Zhou H. Endothelial cell activation in central nervous system inflammation. J Leukoc Biol. 2017;101:1119–32. Available from: https://doi.org/10.1189/jlb.3ru0816-352rr
10. Baizabal-Carvallo JF, Barragán-Campos HM, Padilla-Aranda HJ, Alonso-Juarez M, Estañol B, Cantú-Brito C, et al. Posterior reversible encephalopathy syndrome as a complication of acute lupus activity. Clin Neurol Neurosurg. 2009;111:359–63. Available from: https://doi.org/10.1016/j.clineuro.2008.11.017
11. Kivity S, Agmon-Levin N, Zandman-Goddard G, Chapman J, Shoenfeld Y. Neuropsychiatric lupus: A mosaic of clinical presentations. BMC Med. 2015;13:43. Available from: https://doi.org/10.1186/s12916-015-0269-8
12. Stock AD, Gelb S, Pasternak O, Ben-Zvi A, Putterman C. The blood-brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface. Autoimmun Rev. 2017;16:612–9. Available from: https://doi.org/10.1016/j.autrev.2017.04.008
13. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29:1043–9. Available from: https://doi.org/10.3174/ajnr.a0929
14. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219. Available from: https://doi.org/10.1093/eurheartj/eht151
15. Abbott NJ, Mendonça LLF, Dolman DEM. The blood-brain barrier in systemic lupus erythematosus. Lupus. 2003;12:908–15. Available from: https://doi.org/10.1191/0961203303lu501oa
16. Steffen BJ, Breier G, Butcher EC, Schulz M, Engelhardt B. ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro. Am J Pathol. 1996;148:1819–38. Available from: https://pubmed.ncbi.nlm.nih.gov/8669469/
17. Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007;56:3759–69. Available from: https://doi.org/10.1002/art.23035
18. Sato T, Fujii T, Yokoyama T, Fujita Y, Imura Y, Yukawa N, et al. Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum. 2010;62:3730–40. Available from: https://doi.org/10.1002/art.27700
19. Nishimura K, Harigai M, Omori M, Sato E, Hara M. Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroendocrinology. 2008;33:395–403. Available from: https://doi.org/10.1016/j.psyneuen.2007.12.007
20. Gelb S, Stock AD, Anzi S, Putterman C, Ben-Zvi A. Mechanisms of neuropsychiatric lupus: The relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. J Autoimmun. 2018;91:34–44. Available from: https://doi.org/10.1016/j.jaut.2018.03.001
21. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28:1320–27. Available from: https://doi.org/10.3174/ajnr.a0549
22. Mueller-Mang C, Mang T, Pirker A, Klein K, Prchla C, Prayer D. Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance? Neuroradiology. 2009;51:373–83. Available from: https://doi.org/10.1007/s00234-009-0504-0
23. Lamy C, Oppenheim C, Meder JF, Mas JL. Neuroimaging in Posterior Reversible Encephalopathy Syndrome. J Neuroimaging. 2004;14:89-96. Available from: https://pubmed.ncbi.nlm.nih.gov/15095552/
24. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219. Available from: https://doi.org/10.1093/eurheartj/eht151
25. Koob M, Dietmann JL. Encéphalopathie postérieure réversible. Presse Med. 2007;36:437-438. Available from: https://doi.org/10.1016/j.lpm.2007.02.005